Isoniazid Preventive Therapy: Do the Risks Outweigh the Benefits In Pregnant Women with HIV?

Published Date:

03/13/2018

Publication:

aidsmap

Isoniazid preventive therapy (IPT) during and after pregnancy in women living with HIV on antiretroviral therapy (ART) in tuberculosis (TB) endemic areas in Africa, Asia and Haiti resulted in serious adverse events quite possibly attributable to isoniazid with no significant reduction in TB cases, participants heard last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2018) in Boston.

Access Full Article

Clinical Trials

A5354/EARLIER: Effect of Antiretroviral Treatment Initiated...

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More